Scientific corner

Combination therapy with Adalimumab plus intensive granulocyte and monocyte adsorptive apheresis induced clinical remission in a Crohn’s disease patient with the loss of response to scheduled Adalimumab maintenance therapy: A case report

Keiji Ozeki 1Satoshi TanidaTakashi MizushimaTsutomu MizoshitaHironobu TsukamotoYoshikazu HirataKenji MurakamiTakaya ShimuraHiromi KataokaTakeshi KamiyaTakashi Joh, Intern Med. 2012;51(6):595-9.

A 21-year-old Caucasian man with a diagnosis of Crohn’s disease (CD) at the age of 14 was admitted to our hospital due to CD flare-up while under scheduled adalimumab (ADA) maintenance therapy. His symptoms remained virtually unchanged following high dose corticosteroid therapy. Seven days later, combination therapy with ADA plus intensive granulocyte/monocyte adsorptive apheresis (GMA) was initiated, which induced clinical remission. Therefore, combination therapy with ADA plus intensive GMA appears to be an effective therapeutic option for patients with severe CD while under scheduled ADA maintenance therapy.

Contact UsFor more information

Contact Us